RESEARCH PAPER
Osteonecrosis of alveolar mandibular bone in the patient treated with dental implants due to application of antiresorptive madication. A case report
| 1 | Department of Prosthetic Dentistry, Faculty of Medicine and Dentistry, Medical University of Warsaw, Poland |
| 2 | Zakład Chirurgi Stomatologicznej WUM |
| 3 | Klinika Nowotworów Głowy i Szyi Centrum Onkologii - Insytut im. Marii Skłodowskiej - Curie w Warszawie |
| 4 | Katedra Protetyki Stomatologicznej Instytutu Stomatologii Warszawskiego Uniwersytetu Medycznego |
Prosthodontics 2015;65(3):260–265
REFERENCES (10)
1.
Aghaloo T. L., Felsenfeld A.L., Tetradis S.:Osteonecrosis of the Jaw in a Patient onDenosumab. J. Oral Maxillofac. Surg., 2010,68, 959-963.
2.
Boquete-Castro A., Gomez-Moreno G.,Calvo-Guirado J. L., Aguilar-Salvatierra A.,Delgado-Ruiz R. A.: Denosumab and osteonecrosisof the jaw. A systematic analysisof event reported in clinical trials. Clin. OralImpl. Res., 2015, 1-9.
3.
Pichardo S.E.C., Kuypers S. C.C., vanMerkesteyn J.P.R.: Denosumab osteonecrosisof the mandible: A new entity? A case report. J.Cranio-Maxillo-Facial Surg., 2013, 41, 65-69.
4.
Alons K., Kuijpers S.C.C., de Jong E., vanMerkesteyn J.P.: Treating low- and medium--potency bisphosphonate–related osteonecrosisof the jaws with a protocol for the treatmentof chronic suppurative osteomyelitis: reportof 7 cases., Oral Surg. Oral Med. OralPathol. Oral Radiol. Endod., 2009, 107, 1-7.
5.
Pazianas M., Miller P., Blumentals W. A.,Bernal M., Kothawala P.: A review of theLiterature on Osteonecrosis of the Jaw inPatients with Osteoporosis Treated withOral Bisphosphonates: Prevalence, RiskFactors, and Clinical Characteristics. ClinicalTherapeutics, 2007, 29, 8, 1548-1558.
6.
Allen M. R., Burr D. B.: The Pathogenesis ofBisphosphonate- Related Osteonecrosis of theJaw: So Many Hypotheses, So Few Data. J.Oral Maxillofac. Surg., 2009, 67, 61-70.
7.
Anastasilakis A. D., Toulis K.A., Polyzos S.A., Anastasilakis C. D., Makras P.: Long-termtreatment of osteoporosis: safety and efficacyappraisal of denosumab. Therapeutics andClinical Risk Management, 2012, 8, 295-306.
8.
Zhou Z., Chen C., Zhang J., Ji X., Liu L.,Zhang G., Cao X., Wang P.: Safety of denosumabin postmenopausal women with osteoporosisor low bone mineral density: a meta--analysis., Int. J. Clin. Exp. Pathol., 2014, 7,2113-2122.
9.
Migliorati C., Schubert M., Peterson D.:Bisphosphonate-associated osteonecrosis ofmandibular and maxillary bone. Cancer 2005,104, 83-88.
10.
Kuhl S., Walter C., Ascham S,, Pfeffer R.:Bisphosphonate-related osteonecrosis of thejaws – a review. Oral Oncol., 2012, 48, 10,938.
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.